{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-25-000034","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.191020+00:00","generated_at":"2026-05-17T17:29:20.773004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Akebia Q2 2025 net income $0.2M vs loss; Vafseo rev $13.3M, DaVita pilot in 100+ clinics","bullets":["Net income $0.2M (vs net loss of $8.6M in Q2 2024); total revenue $62.5M, up 43%.","Vafseo net product revenue $13.3M; prescription demand grew ~55% QoQ; >725 prescribers.","DaVita begins operational pilot in August at 100+ clinics; DCI/IRC protocols by Sept.","Auryxia net revenue $47.2M, up from $41.2M; no ANDA approved despite LOE in March.","Cash $137.3M; company believes financed to profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-25-000034","json":"https://secwatch.observer/filing/0001517022-25-000034.json","markdown":"https://secwatch.observer/filing/0001517022-25-000034.md","text":"https://secwatch.observer/filing/0001517022-25-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000034/0001517022-25-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000034/akba-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:29:20.773004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}